AKT1 and lung carcinoma: Several drugs targeting the PI3K/Akt signaling pathway [13], including buparlisib (PI3K inhibitor), MK2206 (Akt inhibitor), and perifosine (dual PI3K/Akt inhibitor), are undergoing clinical trials as lung cancer treatments [14,15,16].